1180 related articles for article (PubMed ID: 19052054)
21. Physiological effects of roflumilast at rest and during exercise in COPD.
O'Donnell DE; Bredenbröker D; Brose M; Webb KA
Eur Respir J; 2012 May; 39(5):1104-12. PubMed ID: 21965226
[TBL] [Abstract][Full Text] [Related]
22. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
Wouters EF; Postma DS; Fokkens B; Hop WC; Prins J; Kuipers AF; Pasma HR; Hensing CA; Creutzberg EC;
Thorax; 2005 Jun; 60(6):480-7. PubMed ID: 15923248
[TBL] [Abstract][Full Text] [Related]
23. Walking exercise response to bronchodilation in mild COPD: a randomized trial.
Gagnon P; Saey D; Provencher S; Milot J; Bourbeau J; Tan WC; Martel S; Maltais F
Respir Med; 2012 Dec; 106(12):1695-705. PubMed ID: 22999808
[TBL] [Abstract][Full Text] [Related]
24. [Lung function and exercise tolerance after treatment with salmeterol or ipratropium bromide in chronic obstructive pulmonary disease].
Grzanka A; Pitsch T; Krzywiecki A; Rogala B
Pol Merkur Lekarski; 2004 Sep; 17(99):208-11. PubMed ID: 15628041
[TBL] [Abstract][Full Text] [Related]
25. Is there any difference between effects of ipratropium bromide and formoterol on exercise capacity in moderate COPD patients?
Akkoca Yildiz O; Onen ZP; Demir G; Eriş Gülbay B; Saryal S; Karabiyikoğlu G
Tuberk Toraks; 2006; 54(2):105-13. PubMed ID: 16924565
[TBL] [Abstract][Full Text] [Related]
26. [Effect of dynamic hyperinflation on exertional dyspnea, exercise performance and quality of life in COPD].
Ozgur ES; Atis S; Kanik A
Tuberk Toraks; 2008; 56(3):296-303. PubMed ID: 18932031
[TBL] [Abstract][Full Text] [Related]
27. Locus of symptom limitation and exercise response to bronchodilation in chronic obstructive pulmonary disease.
Deschênes D; Pepin V; Saey D; LeBlanc P; Maltais F
J Cardiopulm Rehabil Prev; 2008; 28(3):208-14. PubMed ID: 18496322
[TBL] [Abstract][Full Text] [Related]
28. Quality of life measurements and bronchodilator responsiveness in prescribing nebulizer therapy in COPD.
Brophy C; Kastelik J; Gardiner E; Greenstone M
Chron Respir Dis; 2008; 5(1):13-8. PubMed ID: 18303097
[TBL] [Abstract][Full Text] [Related]
29. Tiotropium in COPD patients not previously receiving maintenance respiratory medications.
Adams SG; Anzueto A; Briggs DD; Menjoge SS; Kesten S
Respir Med; 2006 Sep; 100(9):1495-503. PubMed ID: 16698259
[TBL] [Abstract][Full Text] [Related]
30. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD.
Beeh KM; Wagner F; Khindri S; Drollmann AF
COPD; 2011 Oct; 8(5):340-5. PubMed ID: 21793716
[TBL] [Abstract][Full Text] [Related]
31. Effect of salbutamol on lung function and chest wall volumes at rest and during exercise in COPD.
Aliverti A; Rodger K; Dellacà RL; Stevenson N; Lo Mauro A; Pedotti A; Calverley PM
Thorax; 2005 Nov; 60(11):916-24. PubMed ID: 15994253
[TBL] [Abstract][Full Text] [Related]
32. Breathing pattern and chest wall volumes during exercise in patients with cystic fibrosis, pulmonary fibrosis and COPD before and after lung transplantation.
Wilkens H; Weingard B; Lo Mauro A; Schena E; Pedotti A; Sybrecht GW; Aliverti A
Thorax; 2010 Sep; 65(9):808-14. PubMed ID: 20805177
[TBL] [Abstract][Full Text] [Related]
33. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease.
O'Donnell DE; Lam M; Webb KA
Am J Respir Crit Care Med; 1999 Aug; 160(2):542-9. PubMed ID: 10430726
[TBL] [Abstract][Full Text] [Related]
34. Exercise duration rather than peak oxygen uptake better correlates with Fev1 and inspiratory capacity in chronic obstructive pulmonary disease.
Metin G; Oztürk L; Duman ES; Demir T
Arch Med Res; 2007 Nov; 38(8):876-81. PubMed ID: 17923270
[TBL] [Abstract][Full Text] [Related]
35. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD.
Voshaar T; Lapidus R; Maleki-Yazdi R; Timmer W; Rubin E; Lowe L; Bateman E
Respir Med; 2008 Jan; 102(1):32-41. PubMed ID: 17996436
[TBL] [Abstract][Full Text] [Related]
36. [The importance of the at risk COPD patients (Stage 0) and clinical differences].
Kömüs N; Tertemiz KC; Sevinç C
Tuberk Toraks; 2008; 56(4):382-9. PubMed ID: 19123073
[TBL] [Abstract][Full Text] [Related]
37. Inspiratory capacity and forced expiratory volume in the first second in exacerbation of chronic obstructive pulmonary disease.
Yetkin O; Gunen H
Clin Respir J; 2008 Jan; 2(1):36-40. PubMed ID: 20298302
[TBL] [Abstract][Full Text] [Related]
38. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.
Singh D; Brooks J; Hagan G; Cahn A; O'Connor BJ
Thorax; 2008 Jul; 63(7):592-8. PubMed ID: 18245142
[TBL] [Abstract][Full Text] [Related]
39. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease.
O'Donnell DE; Lam M; Webb KA
Am J Respir Crit Care Med; 1998 Nov; 158(5 Pt 1):1557-65. PubMed ID: 9817708
[TBL] [Abstract][Full Text] [Related]
40. Three-minute constant rate step test for detecting exertional dyspnea relief after bronchodilation in COPD.
Borel B; Wilkinson-Maitland CA; Hamilton A; Bourbeau J; Perrault H; Jensen D; Maltais F
Int J Chron Obstruct Pulmon Dis; 2016; 11():2991-3000. PubMed ID: 27942208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
